O'Day Daniel Patrick 4

What Happened Daniel P. O'Day, Chairman & CEO and a director of Gilead Sciences, sold a total of 10,000 shares on April 28, 2026 in two open-market transactions. The filing shows 6,950 shares at $128.79 (proceeds $895,075) and 3,050 shares at $130.01 (proceeds $396,534), for aggregate proceeds of approximately $1,291,609. These were sales (S) and thus represent insider disposals rather than purchases.

Key Details

• Transaction dates: April 28, 2026. Report filed April 29, 2026 (timely).
• Reported trades: 6,950 shares at $128.79 ($895,075) and 3,050 shares at $130.01 ($396,534); total 10,000 shares for ~$1,291,609.
• Footnotes: Transactions executed pursuant to a Rule 10b5-1 trading plan adopted Feb 28, 2025 (F1). Reported sale-price ranges: $128.41–$129.325 (F2) and $129.42–$130.47 (F3); the filing notes a more detailed per-price breakdown is available on request.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Transaction code: S = Sale (open market or private sale).

Context Sales conducted under a pre-established 10b5-1 plan are typically scheduled transactions and are common for executives managing regular share disposition; they do not necessarily signal a change in the insider’s view on the company. For retail investors, purchases generally carry more informational weight than routine sales, but notable insider sales can still be relevant when assessing insider conviction and overall insider activity trends.